Nesli Basgoz, MD
Infectious Disease · Boston, MANPI 1841265238
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $857,418 of the $901,324 with a category attached, or 95.1%. Every reported general payment came from a single manufacturer, AbbVie. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $42,920 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$901K
What the payments were for
- Speaking & faculty fees$857,41895%
- Travel & lodging$42,3005%
- Food & beverage$1,6060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $901,324 |
How this compares
$901,324 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 75 | $163,450 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 34 | $134,839 |
| TivicayDolutegravir Sodium | 59 | $129,923 |
| JulucaDolutegravir/Rilpivirine | 37 | $129,605 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 19 | $70,437 |
| IsentressRaltegravir Potassium | 11 | $26,420 |
| Darunavir | 16 | $17,504 |
| Lamivudine | 19 | $3,676 |
| Ritonavir | 15 | $1,753 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $642 |
| Ciprofloxacin Hcl | 20 | $612 |
| Atorvastatin Calcium | 49 | $551 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $495 |
| FenofibrateFenofibrate Nanocrystallized | 21 | $462 |
| Metoprolol Succinate | 14 | $375 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
- Jay FishmanBoston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.